Clinical Trial News and Research

RSS

Single VRC01 antibody infusion could suppress HIV level in people not taking ART

A single infusion of a powerful antibody called VRC01 can suppress the level of HIV in the blood of infected people who are not taking antiretroviral therapy (ART), scientists at the National Institutes of Health report in a paper published today.

24 Dec 2015

Hepatitis C virus linked to increased risk of developing Parkinson's disease

The hepatitis C virus may be associated with an increased risk of developing Parkinson's disease, according to a study published in the December 23, 2015, online issue of Neurology®, the medical journal of the American Academy of Neurology.

24 Dec 2015

Closing patient knowledge gap could encourage cancer patients to enroll in clinical trials

A five-center national study led by Neal Meropol, MD, and a team of researchers from Case Western Reserve University School of Medicine and University Hospitals Case Medical Center demonstrated that a little information goes a long way in encouraging cancer patients to enroll in clinical trials, a decision that could be potentially lifesaving.

24 Dec 2015

Opicapone simplifies levodopa-related motor fluctuation treatment

Once-daily opicapone is effective for the treatment of end-of-dose motor fluctuations in patients receiving levodopa for Parkinson’s disease, phase III study findings show.

23 Dec 2015

UMass Medical School and UMass Lowell collaborate on new cyberinfrastructure technology to improve health care

Researchers at UMass Medical School and UMass Lowell are collaborating on a new cyberinfrastructure technology that will enable patients, researchers and physicians to transport and store large quantities of data, including sensitive information, through a secure system.

23 Dec 2015

FDA approves Uptravi tablets to treat adults with pulmonary arterial hypertension

On December 21, the U.S. Food and Drug Administration approved Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive, and debilitating rare lung disease that can lead to death or the need for transplantation.

22 Dec 2015

Study shows more patients with advanced NSCLC may benefit from pembrolizumab

More patients with advanced non-small-cell lung cancer (NSCLC) could benefit from pembrolizumab, says Professor Roy Herbst, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, presenting promising results from the pivotal phase 2/3 KEYNOTE-010 trial at the first ESMO Asia Congress in Singapore), in conjunction with a publication in The Lancet.

22 Dec 2015

Baxalta announces initial results from ADYNOVATE Phase 3 trial for treatment of hemophilia patients

Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced initial results from a Phase 3 clinical trial of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].

22 Dec 2015

Wnt5a protein acts on tumor-surface proteins to accelerate spread of CLL cells

Building upon previous research, scientists at University of California, San Diego School of Medicine and UC San Diego Moores Cancer report that a protein called Wnt5a acts on a pair of tumor-surface proteins, called ROR1 and ROR2, to accelerate the proliferation and spread of chronic lymphocytic leukemia (CLL) cells, the most common form of blood cancer in adults.

22 Dec 2015

New treatment strategy may take pain away

A brain region controlling whether we feel happy or sad, as well as addiction, is remodeled by chronic pain, reports a new Northwestern Medicine study.

22 Dec 2015

Immunotherapy more effective than chemotherapy in treating patients with advanced lung cancer

A new study has found immunotherapy to be more effective than chemotherapy in treating most previously treated patients with advanced lung cancer, and demonstrated effectiveness in a wider population of people than previously known to benefit from the therapy.

22 Dec 2015

Alexza reports interim results from AZ-002 Phase 2a study in epilepsy patients

Alexza Pharmaceuticals, Inc. today announced interim results of its Phase 2a study of AZ-002 (Staccato alprazolam) in epilepsy patients. AZ-002 produced a dose-related decrease in mean Standardized Photosensivity Range (SPR), the primary endpoint in the study.

21 Dec 2015

Nuvo Research announces topline results from WF10 Phase 2 trial for treatment of allergic rhinitis

Nuvo Research Inc., a life sciences company with growing revenues and a diverse portfolio of topical products, today announced the results of its investigational Phase 2 clinical trial of WF10 (Trial) for the treatment of allergic rhinitis.

21 Dec 2015

Mirati announces initiation of glesatinib Phase 2 clinical trial in NSCLC patients

Mirati Therapeutics, Inc. today announced that the Phase 2 clinical trial of glesatinib (MGCD265) has commenced. The Company also announced that "glesatinib" is the proposed generic name for MGCD265.

21 Dec 2015

SciClone plans to pursue development of SGX942 in the Greater China market

SciClone Pharmaceuticals, Inc. today announced plans to pursue development and registration of SGX942 in the Greater China market, for the treatment of oral mucositis.

21 Dec 2015

Combination therapy can help overcome endocrine resistance in women with advanced breast cancer

Data collected in Japanese and Korean patients included in the global PALOMA3 trial provides evidence that combining palbociclib with fulvestrant is an effective strategy to overcome endocrine resistance in women with hormone receptor positive (HR+), HER2 negative (HER2-) advanced breast cancer.

20 Dec 2015

New discovery may soon make prostate cancer cells easier to destroy

A newly discovered connection between two common prostate cancer treatments may soon make prostate cancer cells easier to destroy. Drugs that could capitalize on the discovery are already in the pipeline, and a clinical trial to test whether the finding could improve treatments for prostate cancer patients could be only a few years away.

20 Dec 2015

FDA approves Fenix Continence Restoration System to treat fecal incontinence

The U.S. Food and Drug Administration today approved the Fenix Continence Restoration System to treat fecal incontinence in patients who are not candidates for, or have previously failed, medical or other surgical options.

20 Dec 2015

DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

DS Biopharma, a privately held biopharmaceutical company, today announced the successful completion of a Phase I trial with an oral formulation of the active pharmaceutical ingredient DS102 (15-HEPE) which is being explored for the treatment of fatty liver disorders, such as non-alcoholic steatohepatitis (NASH) and pulmonary disorders, such as idiopathic pulmonary fibrosis (IPF).

18 Dec 2015

Clinical trial data indicate that screening reduces mortality from ovarian cancer

Screening appears to reduce mortality due to ovarian cancer, according to the results of The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) trial published in the Lancet yesterday.

18 Dec 2015

Clinical Trial News and Research

Single VRC01 antibody infusion could suppress HIV level in people not taking ART

Hepatitis C virus linked to increased risk of developing Parkinson's disease

Closing patient knowledge gap could encourage cancer patients to enroll in clinical trials

Opicapone simplifies levodopa-related motor fluctuation treatment

UMass Medical School and UMass Lowell collaborate on new cyberinfrastructure technology to improve health care

FDA approves Uptravi tablets to treat adults with pulmonary arterial hypertension

Study shows more patients with advanced NSCLC may benefit from pembrolizumab

Baxalta announces initial results from ADYNOVATE Phase 3 trial for treatment of hemophilia patients

Wnt5a protein acts on tumor-surface proteins to accelerate spread of CLL cells

New treatment strategy may take pain away

Immunotherapy more effective than chemotherapy in treating patients with advanced lung cancer

Alexza reports interim results from AZ-002 Phase 2a study in epilepsy patients

Nuvo Research announces topline results from WF10 Phase 2 trial for treatment of allergic rhinitis

Mirati announces initiation of glesatinib Phase 2 clinical trial in NSCLC patients

SciClone plans to pursue development of SGX942 in the Greater China market

Combination therapy can help overcome endocrine resistance in women with advanced breast cancer

New discovery may soon make prostate cancer cells easier to destroy

FDA approves Fenix Continence Restoration System to treat fecal incontinence

DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

Clinical trial data indicate that screening reduces mortality from ovarian cancer

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer